vimarsana.com
Home
Live Updates
Galapagos to showcase CAR-T point-of-care manufacturing and
Galapagos to showcase CAR-T point-of-care manufacturing and
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia , with or without Richter’s Transformation , responded to treatment 1 GLPG5201 showed no cytokine... | June 5, 2023
Related Keywords
Germany ,
Mechelen ,
Region Flamande ,
Belgium ,
Japan ,
Sandra Cauwenberghs ,
Margotj Pont ,
Leticia Alserawan ,
Marieke Vermeersch ,
Nuria Martinez Cibrian ,
Daniel Estban ,
Mercedes Montoro ,
Van Gijsel ,
Julio Delgado ,
Jeevan Shetty ,
Christian Jacques ,
Valentin Ortiz Maldonado ,
Sergi Betriu ,
Exchange Commission ,
European Hematology Association ,
Head Of Clinical Development Oncology At Galapagos ,
Objective Response Rate ,
Clinical Development Oncology ,
Clinical Results ,
Maike Spoon ,
Bayesian Optimal Interval ,
Cancer Journal ,
Galapagos Nv Stock Exchange ,
News ,
Information ,
Press Release ,
Wall ,
,
Nut ,
F ,
Eligible ,
Patients ,
Ith ,
Hronic ,
Lymphocytic ,
Leukemia ,
Dr ,
Without ,
Transformation ,
Esponded ,
O ,
Treatment ,
Howed ,
O Glpg Be0003818359 ,